Technical Analysis for AVTX - Avalo Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 10.54 | -3.35% | -0.37 |
AVTX closed down 1.36 percent on Wednesday, November 20, 2024, on 1.37 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | -3.35% | |
200 DMA Support | Bullish | -3.35% | |
Hammer Candlestick | Bullish | -3.35% | |
Below Lower BB | Weakness | -3.35% | |
Down 3 Days in a Row | Weakness | -3.35% | |
Down 4 Days in a Row | Weakness | -3.35% | |
Oversold Stochastic | Weakness | -3.35% | |
50 DMA Support | Bullish | -4.66% | |
Stochastic Reached Oversold | Weakness | -4.66% | |
Below Lower BB | Weakness | -4.66% |
Alert | Time |
---|---|
2x Volume Pace | about 1 hour ago |
1.5x Volume Pace | about 2 hours ago |
Down 5% | about 2 hours ago |
Fell Below Previous Day's Low | about 2 hours ago |
Fell Below 200 DMA | about 3 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Avalo Therapeutics is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. The company’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biology Cancer Immunotherapy Biomarkers Precision Medicine Targeted Therapy Innovative Therapies Rare Genetic Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biology Cancer Immunotherapy Biomarkers Precision Medicine Targeted Therapy Innovative Therapies Rare Genetic Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 34.46 |
52 Week Low | 3.9501 |
Average Volume | 36,008 |
200-Day Moving Average | 10.48 |
50-Day Moving Average | 11.05 |
20-Day Moving Average | 12.96 |
10-Day Moving Average | 12.50 |
Average True Range | 1.02 |
RSI (14) | 40.12 |
ADX | 30.77 |
+DI | 15.31 |
-DI | 23.64 |
Chandelier Exit (Long, 3 ATRs) | 12.95 |
Chandelier Exit (Short, 3 ATRs) | 13.38 |
Upper Bollinger Bands | 14.75 |
Lower Bollinger Band | 11.18 |
Percent B (%b) | -0.08 |
BandWidth | 27.49 |
MACD Line | 0.14 |
MACD Signal Line | 0.54 |
MACD Histogram | -0.3972 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 12.12 | ||||
Resistance 3 (R3) | 12.06 | 11.60 | 11.91 | ||
Resistance 2 (R2) | 11.60 | 11.29 | 11.63 | 11.84 | |
Resistance 1 (R1) | 11.25 | 11.10 | 11.02 | 11.31 | 11.78 |
Pivot Point | 10.79 | 10.79 | 10.68 | 10.82 | 10.79 |
Support 1 (S1) | 10.44 | 10.48 | 10.21 | 10.50 | 10.02 |
Support 2 (S2) | 9.98 | 10.29 | 10.01 | 9.96 | |
Support 3 (S3) | 9.63 | 9.98 | 9.89 | ||
Support 4 (S4) | 9.69 |